Joint Pain Medicines: Topical Options, Benefits & Risks

Identify the condition and treatment purpose

For osteoarthritis, medicine can support function and participation in rehabilitation. For rheumatoid arthritis, symptom relief sits alongside disease-modifying treatment; it does not replace it. For gout or an infected joint, the management problem is different again.

Write what the medicine is expected to help, how benefit will be judged and when it will be reviewed. “Helps pain” does not tell you whether it changes disease activity, restores tissue or is suitable for long-term use.

Topical NSAIDs and oral NSAIDs

NICE places topical NSAIDs early in knee-OA care, and the 2026 ACR summary also supports topical NSAIDs for knee and hand OA. The site of the joint matters: a topical product is not automatically appropriate for deeper hip pain. NICE medicine context; ACR recommendations.

Oral NSAIDs require review of gastrointestinal bleeding, kidney, liver and cardiovascular risks, pregnancy and current medicines. Reduced systemic exposure from a topical product does not mean zero risk or permission to add an oral NSAID. A pharmacist can check whether two differently branded products contain the same class of medicine.

Acetaminophen/paracetamol and guideline differences

Acetaminophen and paracetamol are names for the same medicine. NICE discourages routine use for OA except selected short-term situations when alternatives are unsuitable; the ACR summary retains a conditional recommendation. That difference should be discussed rather than hidden.

Check all cold, flu and combination pain products to avoid unintentionally duplicating the ingredient. Liver disease, alcohol intake and other medicines can change suitability. This page deliberately does not prescribe a dose or an individual maximum.

Duloxetine, opioids and other prescription choices

Duloxetine may be discussed for selected OA patients; benefit, tolerability and interactions require a prescriber. It should not be treated as proof that the pain is imaginary. Opioids carry important dependence, sedation and other risks and should not be a default response to persistent joint pain.

A medicine review may consider why a drug was started, actual functional benefit, unwanted effects and a supported plan if it needs changing. Do not abruptly stop an opioid, antidepressant or other ongoing prescription. The appropriate withdrawal approach is individualized.

A medicine-reconciliation worksheet

This is an original appointment worksheet, not a medicine-selection algorithm. A prescriber or pharmacist must interpret the information.

When safety symptoms need action

Severe allergic symptoms, difficulty breathing, vomiting blood, black stools or feeling acutely unwell require urgent medical assessment. New jaundice, marked swelling or other suspected medicine problems also deserve prompt advice. This list cannot determine whether a medicine is responsible or rule out a serious problem.

A hot swollen joint with systemic illness is not a reason simply to increase a painkiller. Seek assessment and explain what you have taken. Pain relief can mask symptoms without resolving an infection or another urgent cause.

Products with different delivery routes

A topical herbal cosmetic, a licensed topical NSAID and an oral supplement have different evidence and regulatory roles. A familiar ingredient name cannot establish that two products work equally. Read the actual active ingredients and approved labeling.

When comparing a commercial product, use the evidence checklist and keep the purchasing decision separate from treatment advice. No product endorsement or individualized medicine recommendation is made here.

Common combinations that need a pharmacist check

The NHS NSAID interaction guidance supports checking anticoagulants, steroids, antidepressants, other NSAIDs and blood-pressure medicines. Bring packets or photographs of labels rather than relying on brand names. NHS: NSAID interactions.

Choose an outcome and review the medicine burden

A useful prescription discussion asks what improvement is expected, how soon to review it, which adverse effects require contact and what monitoring is needed. For example: “If this helps me walk, can I use that improvement to follow the rehabilitation plan?”

Ask whether stomach protection is indicated when an oral NSAID is used, and whether kidney, cardiovascular or other risks make it unsuitable. Protection for one risk does not erase the others. Do not combine OTC and prescribed NSAIDs without approval.

Some medicines belong to a different pathway: colchicine may be used for gout flares, whereas urate-lowering treatment aims to prevent crystal accumulation; neither is an ordinary OA treatment. The gout guide explains that distinction. For inflammatory arthritis, use the specialist disease-control and monitoring plan.

If benefit is small and sleepiness, dizziness, constipation or another burden interferes with life, bring this to a review. Changes to long-term opioid, antidepressant or steroid treatment need a supported plan, not abrupt stopping.